Prosecution Insights
Last updated: October 01, 2026
Application No. 18/268,959

SOLID FORMS OF A CDK2 INHIBITOR

Final Rejection §112
Filed
Jun 21, 2023
Priority
Dec 24, 2020 — provisional 63/130,530 +1 more
Examiner
MCDOWELL, BRIAN E
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Pfizer Inc.
OA Round
2 (Final)
74%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
842 granted / 1137 resolved
+14.1% vs TC avg
Strong +31% interview lift
Without
With
+30.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 2m
Avg Prosecution
65 currently pending
Career history
1184
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
16.3%
-23.7% vs TC avg
§102
20.5%
-19.5% vs TC avg
§112
49.6%
+9.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1137 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Status of Claims Claims 1-10, 19, and 24-26 are pending in the instant application. Claims 24-26 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. An action on the merits of claims 1-10 and 19 is contained herein. Information Disclosure Statement The examiner has considered the information disclosure statement filed most recently of record. Previous Objections/Rejections Any rejections or objections stated of record in the office action mailed on 4/9/2026 that are not explicitly addressed herein below, are hereby withdrawn in light of applicant's arguments and/or amendments filed 8/6/2026. Status of Rejections 35 USC § 112 (d) The rejection of claims 2-3 and 6-9 is maintained. Applicant’s amendments, see Remarks, filed 8/6/2026, with respect to the rejection set forth in the Non-Final Office Action mailed 4/9/2026, have been fully considered but are not found persuasive. To reiterate the rejection of record, these claims were rejected as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. When a specific polymorphic form reciting X-ray data, etc. is stated in the generic claim, you cannot have a dependent claim which simply adds additional peaks. These are adding more physical data only. Form 3 as in this case will always have these peaks so it is not really adding any further clarification. This also holds true in the additional C13 peaks of claims 6-9. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. The exclusion of “Form 3” does not obviate the issue since claim 1 also recites specific peaks that are exclusive to Form 3 itself. Thus the crystalline form is drawn to this particular form despite the amendment and the rejection is maintained. Correction is required. Conclusion Claims 2-3 and 6-9 are rejected. Claims 1, 4, 5, 10 and 19 are allowable. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN E MCDOWELL whose telephone number is (571)270-5755. The examiner can normally be reached on 8:30-6 MF. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN MCDOWELL/ Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Jun 21, 2023
Application Filed
Apr 09, 2026
Non-Final Rejection mailed — §112
Aug 06, 2026
Response Filed
Aug 24, 2026
Examiner Interview (Telephonic)
Aug 26, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12747223
N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)QUINOLINE-4-CARBOXAMIDES
3y 3m to grant Granted Sep 29, 2026
Patent 12741943
Sodium 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate monohydrate, its preparation and use
4y 0m to grant Granted Sep 22, 2026
Patent 12741959
Belumosudil Metabolites and Uses Thereof In The Treatment of Chronic Graft-Versus-Host Disease
2y 6m to grant Granted Sep 22, 2026
Patent 12733635
PLATELET STORAGE METHODS AND COMPOSITIONS
4y 2m to grant Granted Sep 15, 2026
Patent 12735403
SALT OF RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, SOLID FORM OF THE SALT, PREPARATION METHOD FOR SAME, AND USES THEREOF
3y 6m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+30.8%)
2y 2m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1137 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month